On June 24, 2026, Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration approved TRYNGOLZA (Olezarsen) to lower triglycerides and reduce the risk of acute pancreatitis in adults with severe hypertriglyceridemia.
Ionis announces FDA approval of a treatment for severe hypertriglyceridemia (sHTG) Read More »
December 2025 — Mission: Cure is pleased to announce a collaboration with Cibus Therapeutics and Greenstone Biosciences, two biotechnology companies working together developing next-generation treatments for pancreatic and gastrointestinal diseases. This partnership reflects Mission: Cure’s commitment to keeping the patient community informed about emerging science and supporting efforts to advance new therapies for chronic pancreatitis.
High triglyceride levels can affect people in different ways. High triglycerides often don’t cause symptoms, so many people don’t realize their levels are elevated until a blood test. When triglycerides get extremely high, they can sometimes cause physical signs (like small yellow skin bumps) and can raise the risk of serious complications, including acute pancreatitis
A Community for People Navigating High Triglycerides Read More »
We have some exciting news for people living with pancreatitis caused by the FCS genetic mutation. On November 18, 2025, the FDA has approved REDEMPLO® (plozasiran), a new treatment from Arrowhead Pharmaceuticals that lowers triglycerides and reduces acute pancreatitis attacks in adults with Familial Chylomicronemia Syndrome (FCS). This is an important step for people with
FDA Approves New Treatment for Familial Chylomicronemia Syndrome (FCS) Read More »
With heavy hearts, Mission: Cure shares the news of the passing of a visionary leader, dedicated advisor, and generous supporter, Sam Shrauger.
Remembering Sam Shrauger Read More »
High triglycerides are one of the leading causes of pancreatitis, and for some people, extremely high levels can be caused by a rare genetic condition called Familial Chylomicronemia Syndrome (FCS). We’re excited to share a new resource created for and by the FCS community in partnership with Arrowhead Pharmaceuticals. This was specifically designed for people
New Resource: Managing Life with FCS – A Peer Support Toolbox Read More »
For people living with IgG4-Related Disease (IgG4-RD), treatment can be complicated. The disease is rare, often misdiagnosed, and can affect many different organs. When it affects the pancreas, it is called Type 1 Autoimmune Pancreatitis (AIP). Steroids are usually the first treatment doctors prescribe because they quickly reduce inflammation, improve symptoms, and induce remission, and
The Risks of Steroid Use for Type 1 Autoimmune Pancreatitis (IgG4-RD) Read More »
With heavy hearts, Mission: Cure shares the news of the passing of a visionary leader, dedicated advisor, and generous supporter, Sam Shrauger.
On April 3, 2025, the FDA approved Uplizna® (inebilizumab-cdon) as the first and only approved treatment for Immunoglobulin G4-related disease (IgG4-RD), the condition behind Type 1 Autoimmune Pancreatitis (AIP). This is a huge milestone. It’s the first time a treatment has been officially approved for this rare, immune-related cause of pancreatitis. For patients living with
Exciting news! On December 19, 2024, the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA (olezarsen), developed by Ionis, as the first-ever treatment for Familial Chylomicronemia Syndrome (FCS). FCS is a rare genetic condition that causes dangerously high triglyceride levels, increasing the risk of severe health complications–especially pancreatitis. This approval is a major milestone—not
FDA Approves First-Ever Treatment for Familial Chylomicronemia Syndrome (FCS) Read More »
Before You Go
Stay up-to-date on the latest Mission: Cure news and developments in pancreatitis care.
